Comparative bioavailability of a generic capsule formulation of the reverse transcriptase inhibitor efavirenz and the innovator product

OBJECTIVE

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that has been used successfully for more than a decade to treat human immunodeficiency virus (HIV) infection. The objective of the current study was to determine the bioequivalence between a generic capsule formulation of efavirenz and the innovator product.

MATERIAL AND METHODS

A total of 41 healthy subjects (34 males and 8 females) received a single 200 mg oral dose of efavirenz as the generic (Ranbaxy-Efavirenz, Ranbaxy Laboratories Ltd.) and innovator (Sustiva, Bristol-Myers Squibb) capsule formulations under fasting conditions in a randomized, 2-way crossover study. Multiple blood samples were collected over 72 hours and plasma concentrations of efavirenz were assayed using an LC/MS/MS method. Pharmacokinetic (PK) parameters were calculated using non-compartmental methods.

RESULTS

Plasma concentrations of efavirenz peaked within 2.5 hours and then declined in a multi-exponential manner for both formulations. At 72 hours post dose, all plasma concentrations of efavirenz were above the LOQ of the assay (10 ng/ml). Mean area under the curve from 0 - 72 hours (AUC0-72) and maximum plasma concentrations (Cmax) of efavirenz for the generic capsule formulation were 22,840 ng x h/ml and 1,199 ng/ml, respectively. Ratios and 90% confidence intervals of PK parameters between the two formulations were within 80.0 - 125.0%, suggesting that the two capsule formulations resulted in similar rate and extent of bioavailability under fasting conditions. Adverse events were similar in nature and frequency for the two formulations.

CONCLUSIONS

Based on the above results, the generic capsule formulation of efavirenz developed by Ranbaxy should be as effective as the innovator product.

Influence of concomitant quinidine administration on dextromethorphan disposition in rats

High doses of dextromethorphan (DM) have been clinically investigated for the treatment of multiple neuronal disorders including neuropathic pain. Several authors have suggested the concomitant administration of DM and a CYP2D6 reversible inhibitor in order to enhance the exposure of DM and limit the exposure to total dextrorphan (DX). The present study proposes to determine whether or not a single dose of quinidine is sufficient to enhance the plasma concentrations of DM in rats and keep those of DX at a minimal level. Oral doses of DM (50 mg/kg) were administered with increasing dose levels of quinidine (0, 2, 20, and 50 mg/kg) to male Sprague-Dawley rats and blood samples were collected over 24 h. Plasma concentrations of DM and total DX were determined using ESI-LC/MS/MS. Quinidine coadministration resulted in a more than twofold increase in the area under the curve of DM with an ED(50) of approximately 2 mg/kg whereas those of total DX were only increased by 21%. These results support the working hypothesis that a single dose of quinidine may enhance the plasma concentrations of DM relative to those of total DX and may therefore improve the treatment of neuropathic pain.

A contract research organization's response to the new FDA guidances for bioequivalence/bioavailability studies for orally administered drug products

The new FDA Guidance for Industry BA and BE Studies for Orally Administered Drug Products--General Considerations and Average, Population, and Individual Approaches to Establishing Bioequivalence imply significant changes in the areas of enrollment, cost, ethics, time, entry, validation applications (EVAs), and statistical and pharmacokinetic methods. The changes from three-period to two-period design for food effect studies, the elimination of most steady state studies, and the analyses of only the active moiety or ingredient are welcome. However, if the current guidances are adopted, additional time will be needed for participants, and more participants will be needed, resulting in higher costs to drug developers. The PK parameters needed to assess BE and the need for replicate designs for drugs with long t1/2 are still unclear. Finally, the advantages of the aggregate property of the FDA metric versus the disaggregate criteria are challenged, and four bioequivalence criteria are proposed.

Iodine status of New Zealand residents as assessed by urinary iodide excretion and thyroid hormones

The aims of this study were (1) to compare various measures of I status, and (2) to assess urinary I and thyroid hormone status of residents of two areas of New Zealand where, before the iodization of salt, goitre was endemic due to low soil I. A total of 189 subjects (102 males, eighty-seven females) were recruited from the Dunedin Blood Transfusion Centre, and 144 (sixty-seven males, seventy-seven females) from the Waikato Blood Transfusion Centre between November 1993 and June 1994. Blood was taken for thyroid hormone assays, and subjects collected a fasting overnight urine specimen, a double-voided fasting urine sample, and a complete 24 h specimen for iodide and creatinine analyses. Positive correlations (P < 0.0001) between daily iodide excretion and iodide concentrations in fasting and double-voided fasting urines, identical median values for iodide concentrations in the three samples, and similar numbers of subjects classified as at risk from I deficiency disorders according to the International Committee for the Control of Iodine Deficiency Disorders/World Health Organization categories (World Health Organization, 1994) confirmed indications from earlier studies that fasting urine samples were suitable for population studies. However 24 h urinary iodide excretion remains the recommended measure for individual I status. Waikato residents excreted more iodide in urine and all measures were significantly greater than for Otago residents. However median urinary iodide excretions for both areas (60 and 76 microgram/d for Otago and Waikato respectively) were considerably lower than those reported previously for New Zealand. Thyroid hormone concentrations were within normal ranges. Our findings suggest that I status of New Zealanders may no longer be considered adequate and may once again be approaching levels of intake associated with clinical I deficiency.

Management of cat and dog bites

An estimated 1 to 2 million Americans are bitten by cats and dogs each year. Most victims are children who are bitten by dogs. Dog and cat bite wounds may appear trivial, but if they are not managed appropriately, they can become infected and may result in functional impairment. Cat bite wounds on the hand have the greatest risk of infection. Pasteurella multocida, isolated in over half of all cat bite wounds and in 20 to 30 percent of dog bite wounds, can cause serious infection with severe complications. Amoxicillin-clavulanate is recommended for the outpatient treatment of dog and cat bite wounds. Tetanus immunization status and the risk of rabies infection should be routinely addressed in bite wound management.

Periodic and nonperiodic burst responses of frog (Rana pipiens) retinal ganglion cells

Neural activity of class 3 retinal ganglion cells was recorded in frog optic tectum, using extracellular microelectrodes. The stimuli were rectangular patches of contrast (light-on-dark or dark-on-light), applied within the previously determined receptive fields, for periods ranging from a few milliseconds to several seconds. ON and OFF responses were recorded for as long as 1 s following stimulation. Poststimulus time histograms revealed two types of responses, labeled periodic and nonperiodic bursters. The periodic bursters were characterized by periods of high activity separated by silent or near-silent intervals. The bursts occurred rhythmically with frequencies roughly between 15 and 50 Hz. Nonperiodic bursters generally showed both broad and sharp peaks in activity, but no regular periodicities. Activity profiles were flat initially, with silent periods appearing after the first few stimulus presentations, suggesting an inhibitory nature of the bursting process. The records were shown to combine the activities of several neurons. Analysis of the waveforms in real time made possible isolation of some units. In these cases, neurons exhibited a high degree of selective synchrony, i.e., the sharing of a portion of the activity profile, and notable differences at other times. These data have implications for the processing of visual information.